What are the advantages of a hospital-based Early Phase Unit?

Image Early Phase Research Unit
Early Phase Oncology Trials

Choosing the right setting for your early phase trial can be challenging. As a sponsor, it’s natural to remain cautious about running more extensive early-phase patient trials in a single Phase I unit due predominantly to the doubt over actually being able to recruit large patient populations. Other points in this discussion include everything from costs and resource availability to in-house expertise, processes and equipment. However, based on years of experience, we can proudly say that efficient recruitment and involving KOLs in a single early phase unit is possible, without a doubt. A single-centre, early-phase trial with patients is cost-effective and has specific benefits over a multi-centre strategy, especially if the early phase unit is in a hospital. So, what are the advantages of a hospital-based Early Phase Unit?

We listed five reasons why Early Phase pharma and biotech companies consider or prefer an early phase / Phase 1 unit located within a hospital. Shortly, it’s a beneficial setup and can move your study to the next level quickly because of:

  1. An inherent focus on patient safety
  2. Plentiful academic experience
  3. A considerable pool of potentially eligible patients
  4. A wide variety of diagnostic procedures
  5. Simplified communication & Smooth execution

 

Safety First

You can be sure that patient safety is a No. 1 priority in any hospital. To ensure the safety and well-being of clinical trial subjects, patients or healthy volunteers, you must ensure maximum safety measures at your site. You should never risk patient safety in first-in-human or Phase 1 clinical trials (or any patient trial for that matter) and perform these studies under controlled conditions with the possibility of close medical team supervision as necessary by the study protocol. 

According to EMA, any Phase 1 unit needs appropriately qualified staff, a vast abundance of required diagnostic equipment, and easy access to an Intensive Care Unit and other hospital facilities. In addition, best practices show that the ICU should be in the same building to ensure smooth patient transfer and care, thus guaranteeing subject safety.

 

Experienced investigators

Having the availability of many experienced investigators is a significant benefit to your clinical study as it can ensure smooth execution throughout the whole timeline. For example, VUL Santaros Klinikos is one of the largest hospitals in Lithuania, with more than 5000 employees, including 1600 medical doctors (MDs) and 2200 nurses. And Biomapas’ Phase 1 unit, BIO1, is right in the middle of all this.

Hospitals are bound to have several ongoing trials in different stages at any one time, and investigators are familiar with offering flexibility to tend to multiple studies. While it’s typical for an early phase unit to work in small teams to perform research activities, having so much expertise in one place allows you to scale up with ease quickly. So, the reach of an in-hospital early phase unit within the patient community often extends as far as the hospital’s complete patient base and its staff. 

Such a wide selection lets you choose from a vast pool of specialists with extensive experience in different therapeutic areas, allows you to avoid study traffic and ensure timely and effective study conduct. In addition, experienced and qualified investigators can be easily approached for study feasibility and provide reliable prospective study patient numbers according to the inclusion/exclusion criteria, which brings us to our third advantage.

 

Rapid, effective patient enrollment

Most commercial Phase I units require a dedicated marketing and subject recruitment division in-house to recruit high volumes of healthy volunteers. The employees that staff these divisions are typically employed solely to recruit volunteers, leading to relatively high overhead costs. In addition, these units will typically rely on external databases to aid in recruiting and retaining potential volunteers for a variety of studies, depending on the subject demographic required.

In a hospital, it’s possible to recruit at a minimal cost and within short time frames for your upcoming and ongoing clinical studies. 

The immense patient pool at their disposal allows early phase units to act immediately if a change in strategy is required to scale up or down recruitment activities on short notice. In addition, non-commercial clinical trials units typically show lower overhead because they employ one or more individuals to cover many aspects of the trials, from subject identification, recruitment, screening, clinical conduct, and post-clinical functions. These individuals may have a dedicated research function, but more often than not, are involved in the day-to-day clinical conduct associated with a hospital clinic.

 

Diagnostic procedures

Although we’re making significant steps in early phase research, we must work hard for results. Regulators put intense stress on patient monitoring and are demanding regarding the investigators and patient protocols, much more than you find in later-phase studies. It’s not an exception when a protocol requires multiple electrocardiograms, including a challenging schedule for PK measurements, biopsies, ancillary consults, a variety of imagings, and plenty of other time-consuming tasks.

Having a clinical trial unit on the hospital premises has an abundance of benefits, with the most important ones being:

  • Easy scheduling of necessary procedures because the equipment and qualified personnel are already within reach.
  • Quick transfer of clinical trial subjects between the facilities when needed;
  • Brief carry out of procedures in established processes.

And perhaps the most critical factor of all is that the increased patient-centric approach increases quality and minimizes the risk of protocol deviations.

 

Simplified communication & smooth execution

A single-centre approach benefits your trial through simplified communication channels, something you cannot achieve when using multiple sites and third-party suppliers. Since you’re working with a single centre to conduct your trial, the sponsor company will speak to only a handful of people to communicate instructions and receive relevant feedback.

Suppose time is of the essence for a clinical trial. In that case, as is frequently the case for early-phase studies, this is a significant advantage because actions can be taken and reported swiftly and consistently. This is not always possible using a multicenter approach.

 

Smooth & timely execution

The last reason we want to mention is that a Phase 1 unit located within a hospital offers the simple, straightforward essential advantage of smooth execution.

  • Having separate diagnostic facilities at the hospital guarantees the safety of the investigators and study participants;
  • Having qualified study staff to coordinate patient admission and ensure confidentiality, if the study protocol requires it;
  • And, most importantly, knowing that the ongoing studies will not disturb other daily department operations, thus guaranteeing the highest quality following relevant SOPs and protocols.

The well-being of patients during the trial and quality are the main pillars to successful study execution.

 

Running a Clinical Trial in Ukraine

Running a Clinical Trial in Ukraine

Despite the fact that Ukraine is the largest country in Eastern Europe with a large population of treatment-naïve patients, well organized public health care sector and significant number of medical sites accredited for clinical trial conduction, country has utilized only 15% of its current potential for hosting clinical trials. During 2017, the European Medicine Agency (EMA) gave positive recommendations on 94 new drug applications and 49 of them were tested in clinical trials in Ukraine. During the same year, the US FDA approved 151 new drugs, and 28 of them were also studied in Ukraine.

read more
What You Need to Know about Running a Clinical Trial in Russia?

What You Need to Know about Running a Clinical Trial in Russia?

Russia is a very perspective country for international clinical trial conduction. The first international clinical trial was set up in Russia about 20 years ago only, and from than country kept a great potential for market development. In 2018 health authorities (HAs) approved 653 clinical trials (CT) in Russian Federation, less in overall numbers compared to the same indicator from 2016 – 898 approved CTs. However, this decrease was observed across all types of clinical trials except for international multicentre clinical trials (IMCT).

read more
The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The number of clinical trials worldwide is increasing more than 10% each year due to the new diseases, further research for better health products and development of new drugs. Though, for a successful clinical trial, there is a major challenge – patient recruitment, which is essential and the most challenging factor due to the increasing number of new clinical trials. In order to achieve the required patient recruitment, sponsors are looking for different solutions.

read more
Running a clinical trial in the Baltic states

Running a clinical trial in the Baltic states

In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more
Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

World Tuberculosis Day is commemorated every year on 24th March to raise awareness of tuberculosis, which is still causing death of nearly 1.5 million people each year, mostly in developing countries. It marks the day in 1882, when Dr. Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. In comparison to other infectious diseases caused by a single infectious agent, tuberculosis is the second biggest killer worldwide.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information